FMS

The Week

ISUL.US rose 12.2% this week, closing at $20.014 versus a prior Friday close of $17.838. The S&P 500 fell 0.47%, leaving the ETF roughly 12.67 percentage points ahead. The week was uneven: it opened Monday 19 October at $18.020 and reached $18.441, moved to $18.824 Tuesday, then dropped as low as $15.500 on Wednesday 21 October before recovering to $18.009. Thursday and Friday pushed higher, with Friday closing at $20.014, just below the week’s high of $20.520. Weekly amplitude was 27.86%, and average daily volume of 86,329 was about 126% above the 60-day median.

Intuitive Surgical This Week

Intuitive Surgical (ISRG.US) gained 6% to close at $452.29, up from $426.70 the prior Friday. It followed a similar pattern: a sharp Wednesday pullback and then a rebound. The stock ended Monday at $433.180 and Tuesday at $438.000, fell to an intraday low of $398.992 on Wednesday before closing at $428.120, then climbed on Thursday and Friday to a close of $452.290, with Friday’s high at $458.450. Weekly amplitude was 13.87%, and daily volume ran about 54% above median.

Leverage & Decay

The product targets twice the daily move in Intuitive Surgical, and rebalances each day to maintain that ratio. Intuitive Surgical rose 6% this week; the theoretical two-times reference was about +12%, while the actual result was +12.2%, a gap of just +0.2 percentage point. That gap is the daily reset effect: the ETF tracks each day’s move, not two times the weekly move. A sell-off followed by a rebound, like Wednesday’s pattern, compounds differently than a straight-line week, so long-term holding does not equal two-times returns.

Intuitive Surgical News

The week’s news centred on the Q3 2026 earnings. Before the 21 October conference call, there was talk of options volatility and implied earnings moves, and some Wall Street analysts laid out a case for Intuitive Surgical reaching $500. On 21 October, the company reported revenue of $3.049 billion, up 22%, with procedures up 15%. It also narrowed its 2026 outlook and booked about $450 million in antitrust-related charges, sending shares lower in after-hours and pre-market trading. By 23 October, Intuitive Surgical outperformed competitors on a strong trading day.

Intuitive Surgical — Analyst Ratings

As of 23 October 2026, 34 institutions cover Intuitive Surgical: 19 rate it buy, 7 overweight, 7 hold, and 1 sell. The consensus rating is buy, with a consensus target of $478.30, roughly 5.7% above the current $452.29. Targets range from $324 to $685, a wide spread. Within the medical devices industry, Intuitive Surgical ranks first among 142 names tracked, with the industry average at 7 covering institutions.

The Week Ahead

Macro releases next week include the Dallas Fed manufacturing index on 26 October, followed by durable goods orders, FHFA house prices and consumer confidence on 27 October. For this leveraged product, the focus stays on Intuitive Surgical itself. The next annual earnings disclosure is set for 19 January 2027 after market close, so not next week. Should Intuitive Surgical swing with macro risk appetite, ISUL.US will amplify that move.

In Short

The week’s 12.2% gain tracked a 6% advance in Intuitive Surgical, with two-times exposure roughly doubling the underlying move and pushing the ETF well ahead of the S&P 500. Ratings lean upward, with the consensus target above spot, but the target range is wide and the post-earnings reaction showed how quickly the name can fall. Decay was marginal this week but reflects daily rebalancing, so the ride depends on the path taken. The next test is whether Intuitive Surgical can hold recent levels, and whether macro prints shift sentiment across healthcare.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.